Columbia Technology | Ventures


The $1000 Genome Revolution

Thursday, June 7, 2012 | 11:15AM - 2:15PM | Aureole Restaurant, 135 W 42nd Street (between 6 Ave/ Broadway), New York

The human genome project was an international, publically funded science research project to decipher the sequence, map the location, and identify the function of human genes on all chromosomes.The project, started in 1990, mapped the genome of a few humans as well as several other species and cost over billions.

The project drove innovation in various chemical reagents, instruments, tools and data analytics resulting in breakthroughs in fast, low-cost sequencing that are starting to enable a variety of uses.

20 years later, the  cost to sequence an entire human genome is approaching just $1000 and generating a true life science revolution with extraordinary implications to health, life and beyond.

Join us and gain unique insights on the disruptive opportunities of this revolutionary advance in life science and human health.

11:15 am - 12:00 noon     Registration and Networking
12:00 noon - 1:00 pm       Luncheon
1:00 pm - 2:15 pm           Presentation & Webcast


NYBA, CME&E or CPPA members:  $70
Non-members:   $90
Webcast :  $20

Click here to register and for more information.


Nancy J. Kelley, JD, MPP
Founding Executive Director
New York Genome Center

Nancy J. Kelley is the Founding Executive Director of NYGC. She has served at the very highest levels of the business, government, nonprofit and academic sectors for over twenty years. Ms. Kelley was formerly senior vice president, business development and strategic operations for Alexandria Real Estate Equities, an investment trust engaged in properties for the life science industry including the East River Science Park project in Manhattan. As a senior executive with Spaulding & Slye Colliers and Colliers International, the life sciences group, she oversaw major development projects for such clients as the National Institutes of Health, Johns Hopkins University, the Massachusetts Institute of Technology and Boston University/ Boston Medical Center.

David Darst
Biotechnology Analyst

David M. Darst, joined OrbiMed in 2007 to identify investments in biotechnology and medical device companies. Mr. Darst is a co-founder of several biotechnology companies including Good Start Genetics.. He also co-founded an internet health company, and worked as a summer associate with McKinsey & Company, Pfizer, and Millennium Pharmaceuticals. Mr. Darst earned an A.B. degree cum laude from Harvard College and an M.B.A. from Harvard Business School. Mr. Darst serves on the board of Potentia Pharmaceuticals, Inc.
David Ferreiro
Executive Director
Sr. Life Science Analyst

David Ferreiro PhD, is an Executive Director and Senior Analyst covering Life Science Tools & Diagnostics. Prior to Oppenheimer, David worked at JMP Securities with Steve Lichtman on the Medical Devices research team. He began his Wall Street career at Banc of America Securities covering biotechnology. He has also worked at Grey Healthcare Group as a biomedical writer and was a Graduate Research Scientist at Albert Einstein College of Medicine. Dave holds a B.A. in Biology from Middlebury College, and an M.S. and a Ph.D. in Microbiology and Immunology from the Albert Einstein College of Medicine.